NO20025302L - Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidler - Google Patents
Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidlerInfo
- Publication number
- NO20025302L NO20025302L NO20025302A NO20025302A NO20025302L NO 20025302 L NO20025302 L NO 20025302L NO 20025302 A NO20025302 A NO 20025302A NO 20025302 A NO20025302 A NO 20025302A NO 20025302 L NO20025302 L NO 20025302L
- Authority
- NO
- Norway
- Prior art keywords
- monoclonal anti
- aromatase inhibitors
- antitumor agents
- her2 antibodies
- her2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57135500A | 2000-05-15 | 2000-05-15 | |
| PCT/EP2001/004468 WO2001087334A1 (en) | 2000-05-15 | 2001-04-19 | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20025302D0 NO20025302D0 (no) | 2002-11-05 |
| NO20025302L true NO20025302L (no) | 2002-11-05 |
Family
ID=24283360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20025302A NO20025302L (no) | 2000-05-15 | 2002-11-05 | Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidler |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1282440A1 (no) |
| JP (1) | JP2003533490A (no) |
| KR (1) | KR20030014223A (no) |
| CN (1) | CN1429118A (no) |
| AU (1) | AU784617B2 (no) |
| BR (1) | BR0110732A (no) |
| CA (1) | CA2409652A1 (no) |
| CZ (1) | CZ20023748A3 (no) |
| EA (1) | EA005931B1 (no) |
| EE (1) | EE200200622A (no) |
| HK (1) | HK1054200A1 (no) |
| HU (1) | HUP0301877A2 (no) |
| IL (1) | IL152389A0 (no) |
| MX (1) | MXPA02011194A (no) |
| NO (1) | NO20025302L (no) |
| NZ (1) | NZ523004A (no) |
| PL (1) | PL360153A1 (no) |
| SK (1) | SK16022002A3 (no) |
| WO (1) | WO2001087334A1 (no) |
| ZA (1) | ZA200209815B (no) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| ES2331646T3 (es) | 2000-05-19 | 2010-01-12 | Genentech, Inc. | Ensayo para la deteccion de genes para mejorar la probabilidad de una respuesta eficaz a una terapia contra el cancer basada en antagonistas de erbb. |
| DK1377298T3 (da) * | 2001-01-26 | 2007-01-02 | Pfizer Italia Srl | Exemestan til behandling af hormon-afhængige lidelser |
| GB2375958B (en) | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
| US7919098B2 (en) | 2002-03-26 | 2011-04-05 | Zensun ( Shanghai ) Sci & Tech Co., Ltd. | ErbB-3 based methods and compositions for treating neoplasms |
| CA2491427A1 (en) * | 2002-07-01 | 2004-01-08 | Savient Pharmaceuticals, Inc. | Compositions and methods for therapeutic treatment |
| FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| NZ552091A (en) * | 2004-07-16 | 2009-09-25 | Pfizer Prod Inc | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody |
| PL1846030T3 (pl) | 2005-01-21 | 2019-05-31 | Genentech Inc | Ustalone dawkowanie przeciwciał her |
| UA95902C2 (ru) | 2005-02-23 | 2011-09-26 | Дженентек, Инк. | Способ увеличения времени развития заболевания или выживаемости у раковых пациентов |
| CA2626337C (en) | 2005-10-19 | 2015-12-29 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| EP2592156B1 (en) | 2007-06-08 | 2016-04-20 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
| JP5705836B2 (ja) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター |
| MX2012008958A (es) | 2010-02-18 | 2012-08-23 | Genentech Inc | Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer. |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
| WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| CN102068429B (zh) * | 2010-12-28 | 2011-12-14 | 西南大学 | 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法 |
| MX2014001766A (es) | 2011-08-17 | 2014-05-01 | Genentech Inc | Anticuerpos de neuregulina y sus usos. |
| US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
| WO2013081645A2 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| CN104220457A (zh) | 2012-03-27 | 2014-12-17 | 霍夫曼-拉罗奇有限公司 | 涉及her3抑制剂的诊断和治疗 |
| WO2014015137A2 (en) * | 2012-07-18 | 2014-01-23 | Angion Biomedica Corp. | Compositions and methods for treating dysproliferative diseases |
| RU2692773C2 (ru) | 2012-11-30 | 2019-06-27 | Ф.Хоффманн-Ля Рош Аг | Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1 |
| SG11201703279XA (en) | 2014-10-22 | 2017-05-30 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| JP2018534291A (ja) | 2015-10-22 | 2018-11-22 | ハバフ セラピューティクス ピーティーワイ エルティーディー | マンモグラフィ乳房密度及び／又は乳癌のリスクを低下させる方法 |
| WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
| CN107417791B (zh) * | 2017-08-17 | 2020-09-22 | 合肥瀚科迈博生物技术有限公司 | 抗人ErbB2双特异性抗体、其制备方法及用途 |
| US11524014B2 (en) | 2019-06-03 | 2022-12-13 | Havah Therapeutics Pty Ltd. | Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
-
2001
- 2001-04-19 PL PL36015301A patent/PL360153A1/xx not_active Application Discontinuation
- 2001-04-19 EP EP01929585A patent/EP1282440A1/en not_active Withdrawn
- 2001-04-19 WO PCT/EP2001/004468 patent/WO2001087334A1/en active IP Right Grant
- 2001-04-19 CN CN01809581A patent/CN1429118A/zh active Pending
- 2001-04-19 NZ NZ523004A patent/NZ523004A/en unknown
- 2001-04-19 BR BR0110732-1A patent/BR0110732A/pt not_active IP Right Cessation
- 2001-04-19 EE EEP200200622A patent/EE200200622A/xx unknown
- 2001-04-19 SK SK1602-2002A patent/SK16022002A3/sk not_active Application Discontinuation
- 2001-04-19 KR KR1020027015223A patent/KR20030014223A/ko not_active Application Discontinuation
- 2001-04-19 HU HU0301877A patent/HUP0301877A2/hu unknown
- 2001-04-19 CA CA002409652A patent/CA2409652A1/en not_active Abandoned
- 2001-04-19 CZ CZ20023748A patent/CZ20023748A3/cs unknown
- 2001-04-19 JP JP2001583801A patent/JP2003533490A/ja not_active Withdrawn
- 2001-04-19 IL IL15238901A patent/IL152389A0/xx unknown
- 2001-04-19 EA EA200201213A patent/EA005931B1/ru not_active IP Right Cessation
- 2001-04-19 AU AU56309/01A patent/AU784617B2/en not_active Ceased
- 2001-04-19 MX MXPA02011194A patent/MXPA02011194A/es not_active Application Discontinuation
-
2002
- 2002-11-05 NO NO20025302A patent/NO20025302L/no not_active Application Discontinuation
- 2002-12-03 ZA ZA200209815A patent/ZA200209815B/en unknown
-
2003
- 2003-09-11 HK HK03106504.3A patent/HK1054200A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20023748A3 (cs) | 2003-04-16 |
| WO2001087334A1 (en) | 2001-11-22 |
| HK1054200A1 (zh) | 2003-11-21 |
| IL152389A0 (en) | 2003-05-29 |
| PL360153A1 (en) | 2004-09-06 |
| CN1429118A (zh) | 2003-07-09 |
| MXPA02011194A (es) | 2003-03-10 |
| JP2003533490A (ja) | 2003-11-11 |
| NO20025302D0 (no) | 2002-11-05 |
| EE200200622A (et) | 2004-06-15 |
| EP1282440A1 (en) | 2003-02-12 |
| CA2409652A1 (en) | 2001-11-22 |
| KR20030014223A (ko) | 2003-02-15 |
| EA005931B1 (ru) | 2005-08-25 |
| AU784617B2 (en) | 2006-05-18 |
| SK16022002A3 (sk) | 2003-04-01 |
| AU5630901A (en) | 2001-11-26 |
| BR0110732A (pt) | 2003-02-04 |
| HUP0301877A2 (hu) | 2003-09-29 |
| ZA200209815B (en) | 2003-12-03 |
| NZ523004A (en) | 2004-09-24 |
| EA200201213A1 (ru) | 2003-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20025302L (no) | Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidler | |
| DE60222658D1 (de) | Monoklonaler anti-cd-40-antikörper | |
| NO20031642D0 (no) | Humaniserte anti-LT-O-R-antistoff | |
| DK1501856T3 (da) | Anti-HER2 antistofvarianter | |
| CY2012019I1 (el) | Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20 | |
| NO20033387L (no) | Modifiserte antistoffer og fremgangsmåter for anvendelse | |
| NO20054351D0 (no) | Monoklonalt antistoff og hybridom som produserer dette | |
| DK1390389T3 (da) | Cripto-blokerende antistoffer og anvendelser deraf | |
| NO20032549L (no) | Humaniserte antistoffer som gjenkjenner beta-amyloid-peptid | |
| HUP0300841A3 (en) | Agonist anti-trk-c monoclonal antibodies | |
| NO20044347L (no) | Anti-alfavbeta6-antistoff | |
| IS8115A (is) | Mótefni sem beint er gegn einkjörnungstogefnaprótíni-1 (MCP-1) og notkun theirra | |
| NO20035366L (no) | Benzoylsulfonamider og sulfonylbenzamidiner for anvendelse som antitumormidler | |
| NO20034405L (no) | Anti-ostepontin-antistoff og anvendelse derav | |
| DE60334076D1 (de) | Monoklonaler anti-mensch-tenascin-Antikörper | |
| DE60223191D1 (de) | Ausgeber für Arzneimittel | |
| AU2003220079A8 (en) | Uses of monoclonal antibody 8h9 | |
| EE200300569A (et) | CD44v6-spetsiifilised antikehad | |
| BR0207810A (pt) | inibidores de deformilase de peptìdeo | |
| DE60105696D1 (de) | Eisenhaltige Proteinzusammensetzung | |
| ATE335203T1 (de) | Test für anti-transglutaminase-antikörper | |
| NO20025281D0 (no) | Peptid-deformylase-inhibitorer | |
| FI20011055A0 (fi) | Heveiiniä sitovat monoklonaaliset vasta-aineet | |
| FI20020807A0 (fi) | Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita | |
| ITPD20000192A0 (it) | Anticorpi policlonali |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |